These observations are consistent with previous reports that TZD can reduce APP misprocessing as well as Aβ deposition in transgenic mouse models of AD (Escribano et al., 2010; Mandrekar-Colucci et al., 2012; Skerrett et al., 2015) as well as in primary neural cultures (Mandrekar-Colucci et al., 2012; Skerrett et al., 2015) and in neural cell lines overexpressing APP (Camacho et al., 2004). This evidence concerns the gene APP and Alzheimer disease.